148 related articles for article (PubMed ID: 8453356)
21. Killing effect of interleukin-2 and interferon-alpha activated leukemic bone marrow in remission on K562 leukemic cells.
Li C; Yan W; Hao Y; Han M; Qiu L; Liu H; Han J; Li X; Feng S
Chin Med J (Engl); 1999 Jan; 112(1):53-5. PubMed ID: 11593642
[TBL] [Abstract][Full Text] [Related]
22. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
23. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
24. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.
Schwinger W; Weber-Mzell D; Zois B; Rojacher T; Benesch M; Lackner H; Dornbusch HJ; Sovinz P; Moser A; Lanzer G; Schauenstein K; Ofner P; Handgretinger R; Urban C
Br J Haematol; 2006 Oct; 135(1):76-84. PubMed ID: 16925797
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy.
Margolin K; Forman SJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S33-8. PubMed ID: 10685656
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
27. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
29. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
[TBL] [Abstract][Full Text] [Related]
30. Cellular immunotherapy of cancer.
Topalian SL; Rosenberg SA
Crit Care Med; 1990 Feb; 18(2 Suppl):S144. PubMed ID: 2298029
[No Abstract] [Full Text] [Related]
31. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy with autologous bone-marrow transplantation: rationale and results.
Bilgrami S; Silva M; Cardoso A; Miller KB; Ascensao JL
Exp Hematol; 1994 Oct; 22(11):1039-50. PubMed ID: 7523161
[No Abstract] [Full Text] [Related]
33. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy of malignant diseases using interleukin 2. Bases, results, trends].
Gause A; Pfreundschuh M
Med Klin (Munich); 1990 Sep; 85(9):561-6, 570. PubMed ID: 2233615
[No Abstract] [Full Text] [Related]
35. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
36. [Care of advanced tumor treated by interleukin-2 and lymphokine-activated killer cells].
Wu Y; Li LC
Zhonghua Hu Li Za Zhi; 1994 Nov; 29(11):654-6. PubMed ID: 7614584
[No Abstract] [Full Text] [Related]
37. IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
Nagayama H; Takahashi S; Takahashi T; Ogami K; Ikebuchi K; Tojo A; Tani K; Asano S
Bone Marrow Transplant; 1999 Jan; 23(2):183-5. PubMed ID: 10197806
[TBL] [Abstract][Full Text] [Related]
38. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
[TBL] [Abstract][Full Text] [Related]
40. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
